Global Thrombocytopenia Treatment
Market Dynamics
The Thrombocytopenia
Treatment Market is driven by increasing prevalence of thrombocytopenia globally.
The risk of developing thrombocytopenia is much higher for chronic Hepatitis C
cases. In 2014, according to World Health Organization (WHO), the prevalence of
Hepatitis C was lower in Americas and Europe as compared to Africa and
Pakistan, where the prevalence of chronic liver disorder was 4-6 % higher than
that in Americas and Europe. Liver disease has become a socio economic and
global health problem, as 60-80% of the population develops the disease.
Furthermore, increasing government support for fast-track approval to discover
newer treatments for this disorder and increasing investment in the development
of new drugs by biotechnology and pharmaceutical companies are expected to
propel growth of the thrombocytopenia treatment market during the forecast
period. However, from 2023, thrombocytopenia treatment market is projected to
witness a slowdown in growth due to patent expiration and increasing
availability of generics of Promacta and MabThera.
Thrombocytopenia is a disorder in
which a patient has low level of platelets in the blood. The major causes of
thrombocytopenia are inefficient production of platelets, platelet splenic
sequestration, and accelerative destruction of platelets. The most common
ineffective production of thrombocytes are due bone marrow failure syndrome
such as myelodysplastic syndrome and aplastic anemia. Thrombocytopenia can be
inherited or acquired. In 2014, According to a research article published in
Professional Med J, 2014, entitled Frequency of Thrombocytopenia, the frequency
of thrombocytopenia is higher for people aged 60 years and above, suffering
from non-cirrhotic liver disease. However, rampant discovery coupled with the
ability to clone thrombopoietin has resulted in new treatment opportunities for
clinical manifestation.
* The sample copy includes: Report Summary, Table of Contents,
Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1484
More specific treatment plans
usually depend on the underlying etiology of thrombocytopenia. In most cases
the underlying cause of thrombocytopenia is not known, especially in the case
of severe bleeding. In September 2015, Lusutrombopag, an orally bioavailable,
small molecule thrombopoietin (TPO) receptor agonist developed by Shionogi
Inc., received approval by Pharmaceuticals and Medical Devices Agency of Japan.
Lusutrombopag helped enhance chronic liver disease (CLD) associated with
thrombocytopenia for patients scheduled to undergo invasive procedures.
Lusustrombopag acts specifically on human thrombopoietin (TPO) receptors and
stimulates signaling pathways that trigger the proliferation and
differentiation of bone marrow cells into megakaryocytes. Thus, increasing the
blood platelet count. However, patients treated with Lusustrombopag further
showed higher counts of blood leukocytes and erythrocyte. Furthermore, in June
2017, FDA accepted application for new oral investigational drug, Tavalisse
(fostamatinib disodium), by Rigel Pharmaceuticals, Inc. This drug is designed
to inhibit the spleen tyrosine kinase and treat patients suffering from chronic
or persistent immune thrombocytopenia.
Another drug Eltrombopag by
Novartis, an oral, non-peptide thrombopoietin receptor agonist has shown
efficacy and safety for patients suffering from chronic immune thrombocytopenia
(CIT). The use of this drug is approved in the U.S and registered in Europe.
The low dose of Eltrombopag is effective and safe for the prevention of CIT.
Case Reports Hematology, 2017, reports that long-term usage of thrombopoetin
(TPO) receptor agonists is safe for patients suffering from chronic lymphocytic
leukemia associated with Immune thrombocytopenia, as they are a
non-immunosuppressive drugs.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/thrombocytopenia-treatment-market-1484
Global Thrombocytopenia Treatment
Market – Competitors
Major players in thrombocytopenia
treatment market include 3SBio Inc., Amarillo Biosciences, Inc., Amgen Inc.,
Baxalta Incorporated, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb
Company, Cellerant Therapeutics, Inc., Eisai Co., Ltd., Hansa Medical AB, Intas
Pharmaceuticals Ltd., Merck & Co., Inc., Momenta Pharmaceuticals, Inc.,
Myelo Therapeutics GmbH, Neumedicines Inc., Novartis AG, Pfizer Inc., Prophylix
Pharma AS, Rigel Pharmaceuticals, Inc., Shionogi & Co., Ltd., STATegics,
Inc., and ViroMed Co., Ltd.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1484
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment